- Home
- CPAY vs WAT Comparison
CPAY vs WAT Comparison
Compare CPAY & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPAY
- WAT
- Stock Information
- Founded
- CPAY 1986
- WAT 1958
- Country
- CPAY United States
- WAT United States
- Employees
- CPAY N/A
- WAT N/A
- Industry
- CPAY EDP Services
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- CPAY Technology
- WAT Industrials
- Exchange
- CPAY Nasdaq
- WAT Nasdaq
- Market Cap
- CPAY 22.2B
- WAT 17.8B
- IPO Year
- CPAY 2010
- WAT 1995
- Fundamental
- Price
- CPAY $306.19
- WAT $303.17
- Analyst Decision
- CPAY Buy
- WAT Hold
- Analyst Count
- CPAY 13
- WAT 14
- Target Price
- CPAY $394.33
- WAT $374.07
- AVG Volume (30 Days)
- CPAY 360.1K
- WAT 577.1K
- Earning Date
- CPAY 11-06-2025
- WAT 10-31-2025
- Dividend Yield
- CPAY N/A
- WAT N/A
- EPS Growth
- CPAY 6.87
- WAT 10.77
- EPS
- CPAY 14.72
- WAT 11.09
- Revenue
- CPAY $4,171,325,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- CPAY $14.00
- WAT $7.19
- Revenue Next Year
- CPAY $10.51
- WAT $6.40
- P/E Ratio
- CPAY $20.79
- WAT $27.33
- Revenue Growth
- CPAY 9.22
- WAT 5.89
- 52 Week Low
- CPAY $269.02
- WAT $275.05
- 52 Week High
- CPAY $400.81
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- CPAY 40.92
- WAT 52.92
- Support Level
- CPAY $302.39
- WAT $294.96
- Resistance Level
- CPAY $314.42
- WAT $303.24
- Average True Range (ATR)
- CPAY 6.68
- WAT 8.97
- MACD
- CPAY -1.31
- WAT 0.70
- Stochastic Oscillator
- CPAY 15.06
- WAT 69.04
About CPAY Corpay Inc.
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. Its suite of modern payment solutions helps customers manage vehicle-related expenses, lodging expenses, and corporate payments. Its reportable segments are; Vehicle Payments, Corporate Payments, Lodging Payments, and Other. The group's geographic areas are the United States, Brazil, the United Kingdom, and Other.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.